FyoniBio
Berlin, Germanyfyonibio.comFrom their website, Nov 2026
- GMP
- ISO 9001
Work here? Claim this listing
About
FyoniBio develops biologics and provides bioanalytical support for clinical trials and biologic characterization. It works with biopharmaceutical programs from discovery and cell line development through process development, analytics, and clinical bioanalysis. The company is based in Berlin, Germany.
Services
Cell Line Development
Develops mammalian cell lines for biotherapeutics using CHO and human platforms, including tailored expression systems for complex molecules.
Cell line development
CHOFlow® Cell Line Development
Provides a glycoengineered CHO platform for producing afucosylated monoclonal antibodies and other glycoproteins with enhanced ADCC.
Cell line development
CHOnamite® Cell Line Development
Offers a CHO-based platform for high-yield production of biotherapeutics and classical mAb glycosylation.
Cell line development
GlycoExpress® Cell Line Development
Provides a human expression platform for proteins that require authentic human post-translational modifications and complex glycosylation.
Cell line development
Process Development
Supports upstream and downstream process development and optimization to prepare biologics for scalable manufacturing.
Analytical Services and Bioassays
Performs biochemical analytics and bioassay development to characterize biologics across development stages.
Mass Spectrometry Analytics
Uses mass spectrometry for characterization of critical quality attributes such as glycosylation, integrity, and PTMs.
Clinical Bioanalysis
Develops and runs bioanalytical methods for PK, PD, and immunogenicity studies in clinical samples.
ADME, DMPK & toxicology
3 more services
- Functional and Potency Bioassays
- Bioanalytical Support for Clinical Trials
- Bioanalytical Characterization
- Turnaround
- Typically respond within 24 hours
- What to send
- Blood-derived matrices like serum and plasma
- Tissue-based materials
Capabilities
- Assays and studies
- Bioanalysis
- Process development
- Antibodies
- Immunogenicity
- Oligonucleotides
- CHO
18 more
- PK/PD
- ADCs
- LC-MS/MS
- Cell-based assays
- PK assays
- PD assays
- Immunogenicity assays
- ADA assays
- Neutralizing antibody assays
- Biomarker analysis
- SNP analysis
- Immune cell profiling
- Functional assays
- Ligand binding assays
- Hybrid LC-MS/MS methods
- SEC
- WCX/WAX
- RPC
- Scale and capacity
- Analysis capacity of up to 10,000 samples per year
- High yields > 12 g/L for some mAbs
- High yields > 5 g/L in standard fed-batch processes
- Stability over > 70 population doublings
- Therapeutic areas
- Immuno-oncology
Instruments and platforms
- LC-MS
- Octet BLI
- DRX2
- AlphaScreen
- TÜV Rheinland
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Oligonucleotide
- Recombinant protein
- Biosimilar
- Species and models
- CHO-K1
- CHO-GS-KO
- CHO-DG44
- Human cell lines
- FcγRIIIa
- NK cells
Certifications
As the company states them, with the certificate or registry record where there is one.
ISO 9001:2015Self-reported
Scope: quality management systems
GMPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2022
- Based in
- Berlin, Germany
- Serves
- Global
- General enquiry
- contact@fyonibio.com on their site